Stone Run Capital LLC continued to hold its position in Amgen Inc. (NASDAQ:AMGN) during the first quarter, according to its most recent disclosure with the SEC. The firm owned 1,500 shares of the medical research company’s stock at the end of the first quarter. Stone Run Capital LLC’s holdings in Amgen were worth $246,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. TrimTabs Asset Management LLC increased its position in Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares in the last quarter. Alpha Omega Wealth Management LLC increased its position in Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. increased its position in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares in the last quarter. Nelson Roberts Investment Advisors LLC acquired a new position in Amgen during the first quarter worth about $121,000. Finally, Signature Estate & Investment Advisors LLC increased its position in Amgen by 13.6% in the first quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock worth $130,000 after buying an additional 95 shares in the last quarter. Hedge funds and other institutional investors own 79.53% of the company’s stock.

Amgen Inc. (AMGN) traded down 1.63% on Thursday, reaching $170.72. 549,307 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $174.67 and a 200-day moving average price of $167.36. The company has a market capitalization of $124.57 billion, a P/E ratio of 15.55 and a beta of 1.35. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $184.21.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.84 EPS. Equities research analysts expect that Amgen Inc. will post $12.57 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be issued a $1.15 dividend. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.65%. Amgen’s dividend payout ratio is presently 41.93%.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/stone-run-capital-llc-maintains-stake-in-amgen-inc-amgn/1468346.html.

A number of research firms have recently issued reports on AMGN. Mizuho set a $195.00 price objective on shares of Amgen and gave the company a “buy” rating in a research note on Saturday, May 6th. UBS AG restated a “neutral” rating and issued a $174.00 target price (down from $175.00) on shares of Amgen in a research note on Monday, May 22nd. BidaskClub downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Cann restated a “buy” rating and issued a $203.00 target price (up from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $195.00 target price on shares of Amgen in a research note on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $186.64.

In other news, SVP Cynthia M. Patton sold 2,922 shares of the stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total value of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares in the company, valued at approximately $3,738,641.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.20% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.